Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Real-world analysis of gilteritinib for R/R FLT3-mutated AML

Shai Shimony, MD, Dana-Farber Cancer Institute, Boston, MA, shares some key results from a real-world analysis of gilteritinib for the treatment of relapsed/refractory (R/R) FLT3-mutated acute myeloid leukemia (AML). Dr Shimony discusses the overall survival (OS) observed in patients and the efficacy of this agent, as well as the importance of investigating other treatment combinations in the future. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.